Armata Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Armata Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($173.80M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($18.92M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($69.05M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($36.92M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($23.16M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($22.18M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($19.48M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($16.70M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($12.84M) | Mar 25, 2019 |
| FY2016 | Dec 31, 2016 | ($9.50M) | Mar 27, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.63M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($42.44M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($40.89M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($36.95M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($23.82M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($21.59M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($19.75M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($17.66M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($16.16M) | Mar 25, 2019 |
| FY2016 | Dec 31, 2016 | ($11.86M) | Mar 27, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $9.82M | Mar 19, 2020 |
| FY2019 | Dec 31, 2018 | $8.37M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $2.88M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $5.68M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $3.99M | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | $5.81M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $6.47M | Apr 15, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.76M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($37.55M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($47.42M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($32.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($23.58M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($18.27M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($15.58M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($10.63M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($9.19M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($10.61M) | Mar 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $542.0K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.88M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $8.14M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.21M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.30M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $824.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $224.0K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $875.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $58.0K | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $279.0K | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.88M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $86.44M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $98.36M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $95.83M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $69.77M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $39.52M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $25.45M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $14.55M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $11.14M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $18.15M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $295.48M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $134.46M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $130.43M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $59.75M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $44.37M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $20.66M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $10.86M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $6.85M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.41M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $8.43M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($218.60M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($48.02M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($32.07M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $36.08M | Mar 21, 2025 |
| FY2023 | Dec 31, 2021 | $25.40M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $18.86M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $14.59M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $7.69M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $24.34M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $9.72M | Mar 25, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.49M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.49M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $3.49M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $3.49M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.49M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $3.49M | Mar 18, 2021 |
| FY2016 | Dec 31, 2015 | $7.56M | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | $7.56M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $7.56M | Apr 15, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($501.53M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($327.74M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($308.82M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($239.77M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($202.86M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($179.70M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($157.52M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($138.04M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($394.21M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($381.36M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.69M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $9.29M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $13.52M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $14.85M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $10.29M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $9.65M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $6.03M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $9.66M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.13M | Mar 25, 2019 |
| FY2018 | Dec 31, 2016 | $5.71M | Mar 25, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | (2) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | (2) | Mar 25, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 27, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | (2) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | (3) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | (2) | Mar 25, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 27, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36.43M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 36.18M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 36.12M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 36.14M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 27.11M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 18.69M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 9.92M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 5.07M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 9.50M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | 1.65M | Mar 14, 2018 |